Cargando…

Cardiotoxic effects of angiogenesis inhibitors

The development of new therapies for cancer has led to dramatic improvements in survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising treatment for a wide range of malignancies. However, these drugs are associated with cardiovascular toxicities which can impact optima...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobbin, Stephen J.H., Petrie, Mark C., Myles, Rachel C., Touyz, Rhian M., Lang, Ninian N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812690/
https://www.ncbi.nlm.nih.gov/pubmed/33404052
http://dx.doi.org/10.1042/CS20200305
_version_ 1783637719396646912
author Dobbin, Stephen J.H.
Petrie, Mark C.
Myles, Rachel C.
Touyz, Rhian M.
Lang, Ninian N.
author_facet Dobbin, Stephen J.H.
Petrie, Mark C.
Myles, Rachel C.
Touyz, Rhian M.
Lang, Ninian N.
author_sort Dobbin, Stephen J.H.
collection PubMed
description The development of new therapies for cancer has led to dramatic improvements in survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising treatment for a wide range of malignancies. However, these drugs are associated with cardiovascular toxicities which can impact optimal cancer treatment in the short-term and may lead to increased morbidity and mortality in the longer term. Vascular endothelial growth factor inhibitors (VEGFIs) are associated with hypertension, left ventricular systolic dysfunction (LVSD) and heart failure as well as arterial and venous thromboembolism, QTc interval prolongation and arrhythmia. The mechanisms behind the development of VEGFI-associated LVSD and heart failure likely involve the combination of a number of myocardial insults. These include direct myocardial effects, as well as secondary toxicity via coronary or peripheral vascular damage. Cardiac toxicity may result from the ‘on-target’ effects of VEGF inhibition or ‘off-target’ effects resulting from inhibition of other tyrosine kinases. Similar mechanisms may be involved in the development of VEGFI-associated right ventricular (RV) dysfunction. Some VEGFIs can be associated with QTc interval prolongation and an increased risk of ventricular and atrial arrhythmia. Further pre-clinical and clinical studies and trials are needed to better understand the impact of VEGFI on the cardiovascular system. Once mechanisms are elucidated, therapies can be investigated in clinical trials and surveillance strategies for identifying VEGFI-associated cardiovascular complications can be developed.
format Online
Article
Text
id pubmed-7812690
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78126902021-01-28 Cardiotoxic effects of angiogenesis inhibitors Dobbin, Stephen J.H. Petrie, Mark C. Myles, Rachel C. Touyz, Rhian M. Lang, Ninian N. Clin Sci (Lond) Cardiovascular System & Vascular Biology The development of new therapies for cancer has led to dramatic improvements in survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising treatment for a wide range of malignancies. However, these drugs are associated with cardiovascular toxicities which can impact optimal cancer treatment in the short-term and may lead to increased morbidity and mortality in the longer term. Vascular endothelial growth factor inhibitors (VEGFIs) are associated with hypertension, left ventricular systolic dysfunction (LVSD) and heart failure as well as arterial and venous thromboembolism, QTc interval prolongation and arrhythmia. The mechanisms behind the development of VEGFI-associated LVSD and heart failure likely involve the combination of a number of myocardial insults. These include direct myocardial effects, as well as secondary toxicity via coronary or peripheral vascular damage. Cardiac toxicity may result from the ‘on-target’ effects of VEGF inhibition or ‘off-target’ effects resulting from inhibition of other tyrosine kinases. Similar mechanisms may be involved in the development of VEGFI-associated right ventricular (RV) dysfunction. Some VEGFIs can be associated with QTc interval prolongation and an increased risk of ventricular and atrial arrhythmia. Further pre-clinical and clinical studies and trials are needed to better understand the impact of VEGFI on the cardiovascular system. Once mechanisms are elucidated, therapies can be investigated in clinical trials and surveillance strategies for identifying VEGFI-associated cardiovascular complications can be developed. Portland Press Ltd. 2021-01 2021-01-06 /pmc/articles/PMC7812690/ /pubmed/33404052 http://dx.doi.org/10.1042/CS20200305 Text en © 2021 The Author(s). https://creativecommons.org/licenses/by/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the .
spellingShingle Cardiovascular System & Vascular Biology
Dobbin, Stephen J.H.
Petrie, Mark C.
Myles, Rachel C.
Touyz, Rhian M.
Lang, Ninian N.
Cardiotoxic effects of angiogenesis inhibitors
title Cardiotoxic effects of angiogenesis inhibitors
title_full Cardiotoxic effects of angiogenesis inhibitors
title_fullStr Cardiotoxic effects of angiogenesis inhibitors
title_full_unstemmed Cardiotoxic effects of angiogenesis inhibitors
title_short Cardiotoxic effects of angiogenesis inhibitors
title_sort cardiotoxic effects of angiogenesis inhibitors
topic Cardiovascular System & Vascular Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812690/
https://www.ncbi.nlm.nih.gov/pubmed/33404052
http://dx.doi.org/10.1042/CS20200305
work_keys_str_mv AT dobbinstephenjh cardiotoxiceffectsofangiogenesisinhibitors
AT petriemarkc cardiotoxiceffectsofangiogenesisinhibitors
AT mylesrachelc cardiotoxiceffectsofangiogenesisinhibitors
AT touyzrhianm cardiotoxiceffectsofangiogenesisinhibitors
AT langniniann cardiotoxiceffectsofangiogenesisinhibitors